Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Blindness transient, Blood pressure measurement, Mitral valve incompetence, Presyncope, Thrombosis
Clinical narrative: She had TIA on the right; she felt like she was going to black out on and off; It made her temporarily go blind.; mitral valve regurgitation; she had a blood clot that traveled to the back of her right eye; This spontaneous case was reported by a consumer and describes the occurrence of TRANSIENT ISCHAEMIC ATTACK (She had TIA on the right), THROMBOSIS (she had a blood clot that traveled to the back of her right eye), BLINDNESS TRANSIENT (It made her temporarily go blind.) and MITRAL VALVE INCOMPETENCE (mitral valve regurgitation) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In November 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Nov-2021, the patient experienced THROMBOSIS (she had a blood clot that traveled to the back of her right eye) (seriousness criterion medically significant). On an unknown date, the patient experienced TRANSIENT ISCHAEMIC ATTACK (She had TIA on the right) (seriousness criteria hospitalization and medically significant), PRESYNCOPE (she felt like she was going to black out on and off), BLINDNESS TRANSIENT (It made her temporarily go blind.) (seriousness criterion medically significant) and MITRAL VALVE INCOMPETENCE (mitral valve regurgitation) (seriousness criterion medically significant). The patient was hospitalized for 3 days due to TRANSIENT ISCHAEMIC ATTACK. The patient was treated with ATORVASTATIN CALCIUM (LIPITOR) at a dose of 1 dosage form and ASPIRIN [ACETYLSALICYLIC ACID] for Adverse event, at a dose of 1 dosage form. At the time of the report, TRANSIENT ISCHAEMIC ATTACK (She had TIA on the right), THROMBOSIS (she had a blood clot that traveled to the back of her right eye), BLINDNESS TRANSIENT (It made her temporarily go blind.) and MITRAL VALVE INCOMPETENCE (mitral valve regurgitation) outcome was unknown and PRESYNCOPE (she felt like she was going to black out on and off) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: 170/100 (High) 170/100.         Concomitant medications were not reported. Treatment medication included Beta-blocker.  About 48 hours after the booster dose, the patient felt like she was going to black out on and off. Then it went away. On 20 Nov 2021, the patient had a blood clot that traveled to the back of the right eye and made the patient temporarily go blind. The patient had TIA on the right side of her face and hospitalised for 3 days. the patient got treatment her for the TIA and placed on protocol for stroke: Lipitor; although cholesterol, sugar, and blood pressure were good. One hour after the stroke hit, the blood pressure was 170/100. The patient had a mitral valve regurgitation and having beta blocker every day. the patient was on aspirin every day. the patient had a heart monitor on and will wear it for one more week.  Company comment This case concerns a 47-year-old, female patient with no medical history reported, who experienced the serious unexpected events of thrombosis, transient ischaemic attack, blindness transient, mitral valve incompetence and a non-serious event presyncope. The patient had the booster dose of mRNA-1273 on an unknown date around the first week of November. The patient experienced the event presyncope 48 hours after the third dose of mRNA-1273. The events blindness transient, thrombosis, transient ischaemic attack, mitral valve incompetence occurred on an unknown date after the third dose of mRNA-1273. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2021-406250 (Link).; Sender's Comments: This case concerns a 47-year-old, female patient with no medical history reported, who experienced the serious unexpected events of thrombosis, transient ischaemic attack, blindness transient, mitral valve incompetence and a non-serious event presyncope. The patient had the booster dose of mRNA-1273 on an unknown date around the first week of November. The patient experienced the event presyncope 48 hours after the third dose of mRNA-1273. The events blindness transient, thrombosis, transient ischaemic attack, mitral valve incompetence occurred on an unknown date after the third dose of mRNA-1273. The benefit-risk relationship of mRNA-1273 is not affected by this report.